NIH grants $45 million to study potential Alzheimer’s therapy in clinical trial

The NIH awarded a $45 million grant over 5 years to Burke Neurological Institute to evaluate benfotiamine, a synthetic precursor of thiamine, as a potential therapy for mild Alzheimer’s disease or mild cognitive impairment.
In a release, Burke Neurological Institute (BNI) stated the phase 2 multicenter randomized controlled clinical trial will expand on a pilot study that suggested 300 mg doses of benfotiamine given twice daily significantly slowed the rate of functional decline in 35 participants with mild cognitive impairment or early AD.
“I am particularly excited about this

The NIH awarded a $45 million grant over 5 years to Burke Neurological Institute to evaluate benfotiamine, a synthetic precursor of thiamine, as a potential therapy for mild Alzheimer’s disease or mild cognitive impairment.
In a release, Burke Neurological Institute (BNI) stated the phase 2 multicenter randomized controlled clinical trial will expand on a pilot study that suggested 300 mg doses of benfotiamine given twice daily significantly slowed the rate of functional decline in 35 participants with mild cognitive impairment or early AD.
“I am particularly excited about this